Quality of Life Pre- and Post-Transplant: The Role of Transplant for Treating MDS in Older Patients (After the Results webinar series)

March 17, 2022

This webinar will focus on recent advances in the treatment of myelodysplastic syndrome (MDS) and how quality of life and performance status pre-transplant is critical for older patients.


Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for MDS, which has a median age of 71 at diagnosis. However, early HCT consultation for select older patients is infrequently offered despite no worse survival or quality of life when compared with younger patients.

According to Surveillance, Epidemiology, and End Results (SEER) data from 2013-2017, less than 15% of older patients with high-risk MDS received HCT despite potential eligibility and benefit. Misperceptions persist among referring physicians (community hematologists/oncologists) based on outdated research and practice.

Quality of life assessments are underutilized: Highlighting results from a recently completed clinical trial by the Bone Marrow Transplant Clinical Trials Network (BMT CTN), our transplant and community practice panelists will discuss the importance of quality of life assessment and implications of the most recent research on HCT for older adults with MDS.

Learning Objectives

Participants who engage in this educational intervention will be able to: 

  • Learners will review the BMT CTN 1102 study—a multicenter, biologic assignment trial in older patients with high-risk MDS to define the benefit of HCT over non-HCT therapy.
  • Learners will describe how quality of life and functional performance status are more optimal metrics than age in determining eligibility for HCT.
  • Learners will explain how advances in HCT facilitate improved survival and preserve quality of life.
  • Learners will interpret how this impacts community hematologists/oncologists who see MDS patients and best practices for referring patients early to transplant centers for consult.
Additional information


Samantha Watters
Phone Number: 
+1 (410) 610-4326
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
Course expires: 
Event starts: 
03/17/2022 - 11:30am CDT
Event ends: 
03/17/2022 - 12:30pm CDT
United States
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
Rachel Cusatis
Stephen R Spellman
Corey Cutler

The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest resolution process and resolved.






Tamila Kindwall-Keller, DO


Medical Monitor

Abhinav Chandra

Tempus Labs



ACCME Accreditation Statement: 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

AMA Credit Designation Statement: 

The Medical College of Wisconsin designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Hours of Participation for Allied Health Care Professionals: 

The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.


Please login or register to take this course.